Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Paediatrics and child health indexChapter sections
Purpose and principlesIndications, selection and cautionsMethod and interpretationClinical next stepsRisks, monitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook9 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Incidental findings, consent and confidentiality

Paediatrics and child health · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull

Purpose and principles

Prepare families for unexpected genomic information, obtain valid child-centred consent, distinguish report categories, protect confidentiality while addressing serious familial risk, and document proportionate interpretation, disclosure and follow-up.

Genomic tests can generate information beyond the suspected diagnosis, but vocabulary matters. A primary finding addresses the clinical indication. A secondary or additional finding is deliberately sought outside that question under an explicit policy. An incidental or unsolicited finding is encountered unexpectedly during analysis. Carrier status may be relevant to future reproduction without explaining the child's phenotype. A variant of uncertain significance remains unresolved. Explain which categories the commissioned NHS test may report instead of offering a generic warning that the test could reveal anything.

Consent is a continuing communication process. Describe why testing is proposed, which sample and analysis will be used, possible outcomes, limitations, familial implications, data and sample handling, who receives the report and whether reinterpretation or recontact is routine. Check the person's priorities and invite questions about insurance, family relationships, privacy or future autonomy without amplifying remote risks. Consent does not become valid because a form was signed; understanding, voluntariness, decision-making ability and an opportunity to decline or pause matter.

For children, responsibility depends on the particular decision. A young person with sufficient understanding can consent to or refuse their own test. When a child lacks competence, someone with parental responsibility may usually decide, guided by the child's welfare and current or foreseeable benefit. Involve the child through age-appropriate explanation and assent. Testing that diagnoses current symptoms or enables childhood surveillance can be beneficial. Predictive testing for a solely adult-onset condition with no childhood intervention may be deferred to preserve future choice, unless individual circumstances justify a different balance.

Unexpected findings require verification before disclosure. Confirm identifiers, analytical validity, classification, inheritance and phenotype with the laboratory and clinical genetics team. Ask whether the finding meets the programme's reporting threshold and whether confirmatory testing is needed on a new sample. A severe gene name does not automatically make a variant actionable. Consider penetrance, age of onset, available prevention, psychological impact and whether disclosure falls within the pre-test conversation. If the result is urgent, organise a supported clinical appointment rather than sending an unexplained portal message.

A finding may reveal or suggest an unexpected biological or familial relationship, including donor conception or previously unrecorded consanguinity. Do not promise that testing can never reveal this, and do not disclose speculation from weak evidence. Apply the laboratory and clinical policy, consider what is necessary for the child's care, obtain senior ethical advice and communicate only validated, relevant information. The genomic result should not become a vehicle for investigating family relationships beyond the clinical purpose.

Confidentiality becomes complex because a variant can be simultaneously personal and familial. Begin by explaining why relatives could benefit and support the patient or parents to share a family letter. Explore fear, estrangement, violence or cultural consequences before urging contact. A relative normally receives their own counselling and testing rather than a copy of the child's full record. If consent is refused and an identifiable person faces serious preventable harm, GMC guidance permits a carefully justified balance, but disclosure is not automatic because the condition is inherited.

Before exceptional disclosure, revisit consent and alternatives, define the recipient and information necessary, assess likelihood and seriousness of harm, consider benefit of disclosure, and discuss with senior clinical genetics, Caldicott or medico-legal colleagues. Consider whether disclosure itself could expose the patient or family to danger. If disclosure is justified, share the minimum relevant information through a secure route, tell the patient when safe and document the reasoning. If it is not justified, record the support offered and plan to revisit if circumstances change.

Data governance continues after the consultation. Genomic data and laboratory reports are health records subject to access controls and ordinary information law; raw data should not be moved to personal storage or unapproved consumer platforms. Clarify whether samples may be retained for clinical quality, future testing or research and distinguish each legal or consent basis. Withdrawal may stop future optional use but cannot undo analysis already performed or clinical information already relied upon. Direct requests about data access or deletion to the responsible service rather than making informal promises.

Follow-up needs named ownership. The clinician who requested testing should ensure that a report reaches an appropriate interpreter and that the family receives an explanation. Record whether surveillance, confirmatory testing, family referral or no action is recommended. Give the child an age-appropriate route to learn about results later, especially carrier or adult-onset information. Recontact for variant reclassification cannot be guaranteed indefinitely; explain local arrangements and encourage families to return when health, family planning or contact details change.

Key points

  • Clarify the laboratory's actual analysis and reporting policy before consent; broad genomic data do not mean that every possible disease association will be searched for or returned.
  • Distinguish a secondary or additional finding sought under policy from an incidental or unsolicited finding discovered while answering the primary clinical question.
  • Explain likely outcomes in accessible terms: diagnostic, uncertain, negative, carrier, familial and occasionally unexpected information about health or biological relationships.
  • Assess capacity or competence for the specific decision, involve every child according to understanding and give a competent young person control over their own genomic testing.
  • Parents usually decide for a child lacking competence, but the test should serve the child's interests; adult-onset predictive information without childhood benefit often warrants deferral.
  • A variant of uncertain significance is not a confirmed incidental diagnosis and should not be disclosed as actionable simply because the gene is serious.
  • Confidentiality is the starting point when a result matters to relatives; seek patient-led sharing and disclose without consent only exceptionally to prevent serious harm after senior review.
  • Record what was discussed, preferences, authority, material limitations, the exact reported finding, consultation with genetics and the agreed plan for the child and relatives.

Indications, selection and cautions

Additional finding

A laboratory deliberately analyses a defined gene list beyond the primary indication under an explicit programme and consent policy.

Incidental finding

Analysis for the primary question unexpectedly identifies a potentially relevant result outside the original diagnostic aim.

Carrier result

A heterozygous result may not explain the child's condition but can matter for future reproduction or selected health contexts.

Unexpected relationship finding

Genomic inheritance data suggest an unexpected biological or familial relationship, creating clinical, ethical, communication and possible safety implications.

Familial serious risk

A validated actionable variant could allow an identifiable relative to prevent substantial harm if they knew to seek assessment.

Method and interpretation

  1. 01
    Pre-test scope reviewFirst step
    Why
    Confirm which genes, variant classes and additional findings the laboratory may analyse and report.
    Interpretation and limitations
    Consent must reflect the commissioned pathway, not assumptions about everything technically present in raw data.
  2. 02
    Laboratory finding verification
    Why
    Check identity, assay quality, variant classification, transcript and need for confirmation.
    Interpretation and limitations
    Do not disclose or act on an unvalidated candidate, research signal or uncertain finding as clinical fact.
  3. 03
    Phenotype and actionability review
    Why
    Assess whether the unexpected finding is clinically relevant now or in future.
    Interpretation and limitations
    Penetrance, onset, prevention and compatibility with the person determine consequence beyond classification alone.
  4. 04
    Capacity or competence assessment
    Why
    Establish who can decide about testing and disclosure for this specific child.
    Interpretation and limitations
    Ability is decision-specific and supported communication may enable autonomous choice that age alone would obscure.
  5. 05
    Confidentiality harm-benefit analysis

Clinical next steps

01ConsentDefine scope before samplingFirst stepBroad genomic analysis is proposed for a child or young person.+
  1. 1Confirm the test indication, analytical scope, reporting policy, data handling and possible result categories.
  2. 2Assess decision-making authority and involve the child with developmentally appropriate explanation and support.
  3. 3Document material preferences, family concerns and who should receive and explain the eventual report.
02VerifyInterrogate an unexpected resultThe laboratory reports or queries a finding outside the primary diagnostic aim.+
  1. 1ConfirmatoryCheck analytical validity, classification, identity, phenotype, inheritance and any confirmatory sample requirement.
  2. 2Ask whether return follows the commissioned programme's threshold and the recorded consent discussion.

Risks, monitoring and follow-up

  • Track confirmatory samples, classification review and responsible specialist sign-off before a finding is entered as an active diagnosis.
  • Confirm that the family received an understandable explanation and knows which symptoms, surveillance or referrals actually apply.
  • Review whether a child should be told more about carrier or adult-onset information as competence and personal relevance develop.
  • Document family letters issued and referral routes offered without recording relatives as tested or affected before their own assessment.
  • Reassess confidentiality dilemmas if harm, actionability, family contact or the patient's sharing preference changes.
  • Preserve the exact laboratory report and consent record so future clinicians can distinguish primary, incidental and uncertain findings.

Special situations

Broad data have bounded reporting

Laboratories analyse and return information through validated clinical policies rather than disclosing every association that could be searched in raw sequence.

Uncertainty is not actionability

A VUS in an important gene remains uncertain and does not become a preventive diagnosis because the potential disease is severe.

Family relevance is not public ownership

Inherited information can benefit relatives while remaining confidential health information that requires a proportionate sharing pathway.

Children inherit future choices

Deferring non-actionable adult predictive testing can preserve autonomy, while results received now need a planned path to later disclosure.

Consent cannot erase the past

Stopping optional future use may be possible, but completed analysis and clinically used results cannot simply be withdrawn from history.

Common pitfalls

  1. 01

    Using one generic consent script for every genomic test and reporting policy.

  2. 02

    Returning an unconfirmed candidate or uncertain variant as a diagnosis.

  3. 03

    Assuming parents automatically decide for every competent young person.

  4. 04

    Testing solely adult-onset risk in a child without examining present benefit.

  5. 05

    Telling families that any inherited finding overrides confidentiality automatically.

  6. 06

    Sending a serious unexpected result through an unexplained electronic message.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Paediatrics and child healthOriginal SBA

Childhood predictive testing

Parents request testing of their healthy eight-year-old for a familial adult-onset condition for which childhood surveillance or treatment would not change. What is the best initial approach?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Paediatrics and child health topics →
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • GMC Confidentiality guidanceCore confidentiality duties, family information and serious-harm disclosure principles.
  • GMC Decision making and consentSupported decisions, material information, capacity and valid consent standards.
  • GMC zero to eighteen years guidanceChild competence, parental responsibility, confidentiality and best-interest decision principles.
  • NHS Genomics Education knowledge hubClinical genomic consent, variant classification, secondary findings and familial implications.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
Why
Evaluate exceptional disclosure when consent for family sharing is refused.
Interpretation and limitations
Serious preventable harm, proportionality, minimum information and safety are weighed with senior ethical input.
  • 3Agree clinical relevance, urgency and disclosure method with laboratory and genetics specialists before contact.
    • 03DiscloseExplain without overstatementA validated unexpected finding is appropriate to return.+
    1. 1Arrange a supported conversation that names uncertainty, penetrance, possible action and family implications.
    2. 2Provide written follow-up, referral and surveillance plans while limiting information to validated clinical meaning.
    3. 3Create an age-appropriate future disclosure plan when parents currently receive the result for a young child.
    04ProtectBalance familial risk and privacyA patient refuses to share a serious actionable familial result with an identifiable relative.+
    1. 1Explore reasons, safety and patient-led alternatives and offer a minimal family genetics letter.
    2. 2Seek senior genetics, information-governance and medico-legal advice using GMC confidentiality principles.
    3. 3If disclosure is justified, share only necessary risk information securely and record the full reasoning.